FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W98491101> ?p ?o ?g. }

• W98491101 abstract "Ireland’s biotechnology sector is primed for a revolution. Biotechnology, defined as “the application of knowledge of living organisms, and their components, to industrial products and processes” (Biotechnology Clusters, DTI, 1999), is now considered vital to Ireland future economic success (Harney, Enterprise Ireland, 2002). While exact figures are difficult to obtain, the EU estimates that by 2006 the biotechnology sector will be worth an estimated €250billion, employing more than three million workers (Technology Foresight Report, 1999). To date the sector has not been subjected to concerted academic scrutiny. However, a number of recent studies have begun to investigate the sector. These studies have examined a range of issues, including, the impact of policy tools on the formation of new biotechnology firms in Taiwan (Hsu, Shyu and Tzeng, 2005) and reforms in the biotechnology sector undertaken in Japan (Lynn and Kishida, 2004). A core objective in the Government’s biotechnology strategy is to stimulate growth and development among Ireland’s emerging, indigenous biotechnology sector (Enterprise Ireland 2002). Currently, there are less than 50 indigenous bio-enterprises in Ireland, most are micro companies and at an early stage of developmenti. Furthermore, due to the nature of their activities, most bio-enterprises do not generate any profits in the early years, even bio-companies that have some revenue, tend to invest the bulk of their turnover in long-term product development. By way of strengthening our understanding of this important area, this paper provides an analysis of the state of the biotechnology sector in Ireland. In contrast to its competition, Ireland as a nation was relatively late out of the starting blocks in the race to the forefront of the biotechnology world markets. To lessen the gap between the pioneering and fully developed world leaders in biotechnology, the Irish government prioritised the biotechnology sector as an area for increased development together with major funding programmes into three vital areas, attracting overseas biotechnology companies, increasing the levels of applied research funding and creating and developing indigenous biotechnology start-ups. The paper will aim to provide an insight into the biotechnology sector and the allocation of government investment in this potentially lucrative market both domestically and in a global arena. The paper will try and evaluate if the indigenous companies are allocated the necessary resources to compete globally, as well as assessing the strategies and challenges facing the sector presently and in the future. There are currently 60 biotechnology-based companies on the island of Ireland. 42 of these companies are indigenous and 18 are multinational corporations. Of these 60 firms 40 are involved in biotechnological research and or processes. These include companies involved in biopharmaceutical discovery and manufacturing, diagnostics, pharmaceutical services, bioenvironmental technology and agri-food technologies. They include a mix of indigenous and multi-national companies. 3 This paper will examine the Irish biotechnology sector in relation to the development and funding, as well as what strategies are in place presently and future strategies. The paper will then look at investments in indigenous companies and venture capitalism within the industry through and the examination of government policies towards the industry. Also bio-Ireland funding and all the forms of financing used in the industry and how the SFI allocates its funding and resources in the indigenous biotechnology sector. The paper will conclude with some present challenges facing the industry and look at possible future issues which the Irish biotechnology sector may face in its quest for an increasing share in the global market, as well as the critical role the governments agencies will play in these challenges." @default.
• W98491101 created "2016-06-24" @default.
• W98491101 creator A5032189379 @default.
• W98491101 creator A5037838984 @default.
• W98491101 date "2006-01-01" @default.
• W98491101 modified "2023-10-01" @default.
• W98491101 title "Growing Pains in Irish Biotechnology" @default.
• W98491101 cites W1415001276 @default.
• W98491101 cites W2033719269 @default.
• W98491101 cites W2034600904 @default.
• W98491101 cites W2148309386 @default.
• W98491101 cites W2321876551 @default.
• W98491101 cites W2570844721 @default.
• W98491101 cites W2796955209 @default.
• W98491101 doi "https://doi.org/10.3990/2.268616509" @default.
• W98491101 hasPublicationYear "2006" @default.
• W98491101 type Work @default.
• W98491101 sameAs 98491101 @default.
• W98491101 citedByCount "0" @default.
• W98491101 crossrefType "proceedings-article" @default.
• W98491101 hasAuthorship W98491101A5032189379 @default.
• W98491101 hasAuthorship W98491101A5037838984 @default.
• W98491101 hasBestOaLocation W984911011 @default.
• W98491101 hasConcept C121955636 @default.
• W98491101 hasConcept C138885662 @default.
• W98491101 hasConcept C144133560 @default.
• W98491101 hasConcept C150903083 @default.
• W98491101 hasConcept C154945302 @default.
• W98491101 hasConcept C162324750 @default.
• W98491101 hasConcept C17744445 @default.
• W98491101 hasConcept C18903297 @default.
• W98491101 hasConcept C195487862 @default.
• W98491101 hasConcept C199539241 @default.
• W98491101 hasConcept C2524010 @default.
• W98491101 hasConcept C2776050585 @default.
• W98491101 hasConcept C2778137410 @default.
• W98491101 hasConcept C2780623531 @default.
• W98491101 hasConcept C33923547 @default.
• W98491101 hasConcept C41008148 @default.
• W98491101 hasConcept C41895202 @default.
• W98491101 hasConcept C50522688 @default.
• W98491101 hasConcept C55958113 @default.
• W98491101 hasConcept C64848388 @default.
• W98491101 hasConcept C86803240 @default.
• W98491101 hasConcept C90673727 @default.
• W98491101 hasConceptScore W98491101C121955636 @default.
• W98491101 hasConceptScore W98491101C138885662 @default.
• W98491101 hasConceptScore W98491101C144133560 @default.
• W98491101 hasConceptScore W98491101C150903083 @default.
• W98491101 hasConceptScore W98491101C154945302 @default.
• W98491101 hasConceptScore W98491101C162324750 @default.
• W98491101 hasConceptScore W98491101C17744445 @default.
• W98491101 hasConceptScore W98491101C18903297 @default.
• W98491101 hasConceptScore W98491101C195487862 @default.
• W98491101 hasConceptScore W98491101C199539241 @default.
• W98491101 hasConceptScore W98491101C2524010 @default.
• W98491101 hasConceptScore W98491101C2776050585 @default.
• W98491101 hasConceptScore W98491101C2778137410 @default.
• W98491101 hasConceptScore W98491101C2780623531 @default.
• W98491101 hasConceptScore W98491101C33923547 @default.
• W98491101 hasConceptScore W98491101C41008148 @default.
• W98491101 hasConceptScore W98491101C41895202 @default.
• W98491101 hasConceptScore W98491101C50522688 @default.
• W98491101 hasConceptScore W98491101C55958113 @default.
• W98491101 hasConceptScore W98491101C64848388 @default.
• W98491101 hasConceptScore W98491101C86803240 @default.
• W98491101 hasConceptScore W98491101C90673727 @default.
• W98491101 hasLocation W984911011 @default.
• W98491101 hasOpenAccess W98491101 @default.
• W98491101 hasPrimaryLocation W984911011 @default.
• W98491101 hasRelatedWork W1498748985 @default.
• W98491101 hasRelatedWork W1587149552 @default.
• W98491101 hasRelatedWork W1601193233 @default.
• W98491101 hasRelatedWork W1793955887 @default.
• W98491101 hasRelatedWork W2001533644 @default.
• W98491101 hasRelatedWork W2046319304 @default.
• W98491101 hasRelatedWork W2118445896 @default.
• W98491101 hasRelatedWork W2240435138 @default.
• W98491101 hasRelatedWork W2470906289 @default.
• W98491101 hasRelatedWork W2969574953 @default.
• W98491101 isParatext "false" @default.
• W98491101 isRetracted "false" @default.
• W98491101 magId "98491101" @default.
• W98491101 workType "article" @default.